Roivant Sciences Ltd (ROIV)
Healthcare
Biotechnology
33.30 $
-1.7%
vs. previous close
Closing price · As of: 3. Aug 2026
Roivant Sciences Ltd (ROIV) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -164 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -250 | -196 | -210 | -108 | -267 | -267 | -207 | -173 | -204 | -186 | -196 | -164 | -750 | |
| 5.8 | 7.3 | 5.4 | 2.0 | 4.8 | 4.8 | 2.9 | 1.4 | 1.1 | 0.9 | -8.0 | 30 | 24 | |
| 49 | 49 | 54 | 47 | 72 | 72 | 84 | 83 | 82 | 82 | 105 | 77 | 346 | |
| 51 | 90 | – | – | – | – | – | – | – | – | – | – | – | |
| -35 | 17 | 21 | 16 | 10 | 10 | -53 | 34 | -37 | 7.1 | 9.4 | -601 | -622 | |
| 0.4 | 0.3 | 0.4 | 0.3 | 1.0 | 1.0 | 1.8 | 0.8 | 4.0 | 7.8 | 4.9 | 1.3 | 18 | |
| 0.1 | -36 | 5,233 | 6.9 | -3,294 | -3,294 | 454 | 1,074 | -1,086 | 120 | 149 | 134 | -682 | |
| 6.0 | 6.0 | – | 6.0 | – | – | – | – | – | – | – | – | – | |
| 21 | -216 | 0.0 | 222 | -106 | -106 | -243 | -295 | -208 | 0.0 | 0.0 | -111 | -320 | |
| -7.6 | -7.6 | – | – | – | -1.8 | -49 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 7.5 | 208 | 237 | -33 | -109 | -109 | -273 | -177 | -188 | 63 | 289 | -30 | 134 | |
| -242 | -26 | 5,262 | -178 | -3,664 | -3,664 | -27 | 724 | -1,477 | -1.4 | 242 | -58 | -1,295 | |
| -250 | -197 | -211 | -109 | -268 | -268 | -209 | -173 | -208 | -194 | -192 | -165 | -759 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.